Ascentage Pharma
AAPG
14.94
-1.15
-7.15%
Ascentage Pharma
US · AAPG
#3045 by market cap
Listed 2025
14.94
-1.15
-7.15%
Live - 5344 symbols - heartbeat 240s ago
· 2026-10-08 08:38
Pre-market
14.69
-1.67%
After-hours
14.94
0.00%
Overnight
14.70
-1.61%
- Market cap
- 1.40B
- P/E (TTM)i
- -6.37
- P/Bi
- 16.81
- EPSi
- -1.99
- Div yieldi
- 0.00%
- 52W posi
- 2%
Reader sentiment
Are you bullish or bearish on AAPG?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Ownership Signal how this is computed
Distributing
- The number of reporting institutions decreased by 6 in the most recent period (2026/Q3).
- Total institutional ownership (as a % of shares) was little changed.
Institutional ownership
- Held by institutions
- 29.21% +0.08pp
- Institutions
- 54 -6
- As of
- 2026/Q3 vs. prior period
Ownership vs. money flow
DivergingInstitutions added shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two are pointing in different directions.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Holder types
Mutual Fund14.00%
Individual/Insider12.90%
Private Company10.44%
Public Company3.41%
Sovereign Wealth Fund1.30%
Other57.89%
Top holders as of 2026-04-20
Takeda Pharmaceuticals International AG
6.61% · 6.08M sh
Dajun Yang
6.32% · 5.81M sh
HealthQuest Pharma Limited
3.83% · 3.52M sh
Ming Guo
3.60% · 3.31M sh
Vanguard Capital Management, LLC
3.19% · 2.93M sh
China Universal Asset Management Company Ltd.
2.96% · 2.72M sh
Shaomeng Wang
2.73% · 2.51M sh
Morgan Stanley
1.73% · 1.59M sh
JPMorgan Chase & Co.
1.69% · 1.55M sh
BlackRock
1.46% · 1.34M sh
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
34 filings tracked · 6 buys · 0 sells
| Name | Role | Stake |
|---|---|---|
| Dajun Yang | Chairperson & CEO | 6.32% |
| Ming Guo | Co-Founder | 3.60% |
| Shaomeng Wang | Co-Founder, Chief Scientific Advisor & Non-Executive Director | 2.73% |
| Yifan Zhai | Chief Medical Officer | 0.11% |
| Thomas Knapp | General Counsel | 0.10% |
| Marc Lippman | Independent Non-Executive Director | 0.01% |
| Jin Cao | Head of Finance | 0.01% |
| David Sidransky | Independent Non-Executive Director | 0.01% |
| Wei Ren | Independent Non-Executive Director | 0.00% |
| Changqing Ye | Independent Non-Executive Director | 0.00% |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-05-20 | Yifan Zhai | Chief Medical Officer | Derivative Exercise and Retained | +92,746 | -- |
| 2026-05-20 | Dajun Yang | Chairperson & CEO | Derivative Exercise and Retained | +95,575 | -- |
| 2026-05-19 | Yifan Zhai | Chief Medical Officer | Other Derivative Acquisition | +616,546 | $6.58–8.12 |
| 2026-05-19 | Yifan Zhai | Chief Medical Officer | Other Derivative Acquisition | +804,880 | -- |
| 2026-05-19 | Dajun Yang | Chairperson & CEO | Other Derivative Acquisition | +616,546 | $6.58–8.12 |
| 2026-05-19 | Dajun Yang | Chairperson & CEO | Other Derivative Acquisition | +804,880 | -- |
| 2026-03-17 | Jiuyun Yu | Independent Non-Executive Director | Initial Statement of Beneficial | 0 | -- |
| 2026-03-17 | Marc Lippman | Independent Non-Executive Director | Initial Statement of Beneficial | 0 | -- |
| 2026-03-17 | Marina S. Bozilenko | Independent Non-Executive Director | Initial Statement of Beneficial | 0 | -- |
| 2026-03-17 | David Sidransky | Independent Non-Executive Director | Initial Statement of Beneficial | 0 | -- |
| 2026-03-17 | Thomas Knapp | General Counsel | Initial Statement of Beneficial | 0 | -- |
| 2026-03-17 | Shaomeng Wang | Co-Founder, Chief Scientific Advisor & Non-Executive Director | Initial Statement of Beneficial | 0 | -- |
| 2026-03-17 | Yifan Zhai | Chief Medical Officer | Initial Statement of Beneficial | 0 | -- |
| 2026-03-17 | Changqing Ye | Independent Non-Executive Director | Initial Statement of Beneficial | 0 | -- |
| 2026-03-17 | Dazhong Lu | Non-Executive Director | Initial Statement of Beneficial | 0 | -- |
| 2026-03-17 | HealthQuest Pharma Limited | -- | Initial Statement of Beneficial | 0 | -- |
| 2026-03-17 | Dajun Yang | Chairperson & CEO | Initial Statement of Beneficial | 0 | -- |
| 2026-03-17 | Wei Ren | Independent Non-Executive Director | Initial Statement of Beneficial | 0 | -- |
| 2026-03-17 | Jin Cao | Head of Finance | Initial Statement of Beneficial | 0 | -- |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-10-08 08:38:13 · For reference only, not investment advice and not tailored to your situation.